1. Boutros, C, Tarhini, A, Routier, E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473–486.
Google Scholar | Crossref | Medline2. Michot, JM, Bigenwald, C, Champiat, S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139–148.
Google Scholar | Crossref | Medline3. Hodi, FS, O’Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
Google Scholar | Crossref | Medline4. Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.
Google Scholar | Crossref | Medline5. Khan, SA, Pruitt, SL, Xuan, L, et al. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol 2016; 2: 1507–1508.
Google Scholar | Crossref | Medline6. Lee, YH, Woo, JH, Choi, SJ, et al. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 2009; 18: 9–15.
Google Scholar | SAGE Journals7. Ramos-Casals, Brahmer, JR, Callahan, MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim 2020; 6: 38.
Google Scholar | Crossref | Medline8. Gladman, DD, Ibañez, D, Urowitz, MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.
Google Scholar | Medline9. Abdel-Wahab, N, Shah, M, Lopez-Olivo, MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med 2018; 168: 121–130.
Google Scholar | Crossref | Medline10. Tison, A, Quéré, G, Misery, L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 2019; 71: 2100–2111.
Google Scholar | Crossref | Medline11. Leonardi, GC, Gainor, JF, Altan, M, et al. Safety of programmed death–1 pathway inhibitors among patients with non–small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 2018; 36: 1905–1912.
Google Scholar | Crossref | Medline12. Danlos, F-X, Voisin, AL, Dyevre, V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018; 91: 21–29.
Google Scholar | Crossref | Medline13. Johnson, DB, Sullivan, RJ, Ott, PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2: 234–240.
Google Scholar | Crossref | Medline14. Menzies, AM, Johnson, DB, Ramanujam, S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28: 368–376.
Google Scholar | Crossref | Medline15. Kaur, A, Doberstein, T, Amberker, RR, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience. Medicine 2019; 98: e17348–e17348.
Google Scholar | Crossref | Medline16. Fadel, F, Karoui, K, Knebelmann, B. Anti-CTLA4 antibody–induced lupus nephritis. N Engl J Med 2009; 361: 211–212.
Google Scholar | Crossref | Medline17. Tagliamento, M, Grossi, F, Paolino, S, et al. Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 2019; 11: 873–879.
Google Scholar | Crossref | Medline18. Cortellini, A, Buti, S, Santini, D, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 2019; 24: e327–e337.
Google Scholar | Crossref | Medline19. Sato, K, Akamatsu, H, Murakami, E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018; 115: 71–74.
Google Scholar | Crossref | Medline20. Haratani, K, Hayashi, H, Chiba, Y, et al. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol 2018; 4: 374–378.
Google Scholar | Crossref | Medline21. Ricciuti, B, Genova, C, De Giglio, A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019; 145: 479–485.
Google Scholar | Crossref | Medline22. Wang, DY, Salem, J-E, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 1721–1728.
Google Scholar | Crossref | Medline